- $1.59m
- -$3.49m
- $9.44m
Curis Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Curis - On April 20, 2023, Nasdaq Notified Co That Its Transfer From Nasdaq Global Market To Nasdaq Capital Market Was Approved
Brief: Curis Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Curis Inc reports results for the quarter ended in December - Earnings Summary
Curis Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Curis Reschedules Fourth Quarter 2022 Business Update And Conference Call
Curis Inc expected to post a loss of 13 cents a share - Earnings Preview
Curis Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Curis Announces Additional Encouraging Clinical Data From Takeaim Leukemia Study Of Emavusertib (CA-4948) In Monotherapy R/R Aml And Hrmds
Brief: Curis Provides Third Quarter 2022 Business Update
Curis Inc expected to post a loss of 17 cents a share - Earnings Preview
Curis Inc expected to post a loss of 17 cents a share - Earnings Preview
Curis slides as FDA retains partial hold on two portions of blood cancer study
Brief: Curis Says FDA Allows Patient Enrollment To Resume In Leukemia Study
U.S. STOCKS ON THE MOVE-Cisco, Babcock & Wilcox, Snap, Getty Images
U.S. STOCKS ON THE MOVE-Canadian Solar, Applied Materials, Gold and copper miners
U.S. STOCKS ON THE MOVE-NetEase, Canadian Solar, Keysight Tech, Curis
Curis soars after FDA lifts partial clinical hold on lymphoma drug trial
Brief: FDA lifts partial clinical hold on the Takeaim Lymphoma study of emavusertib